Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 58

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 58
---
%), and price (35.5%) (Sendyona, S., Odeyemi, I., &
Maman, K. “Perceptions and factors affecting pharmaceutical market access: Results from a literature review and survey of stakeholders
in different settings” Journal of Market Access & Health Policy, 4(1), 31660, 2016). In the end, on average, only 20% of
approved new drugs generate revenues that exceed the average R&D investment. (Rosenblatt, M. (2014, December 19) “The Real
Cost of “High-Priced” Drugs,” retrieved from https://hbr.org/2014/11/the-real-cost-of-high-priced-drugs). We
may determine that certain preclinical product candidates or programs do not have sufficient potential to warrant the allocation of resources
toward them. Accordingly, we may elect to terminate our programs for and, in certain cases, our licenses to, such product candidates or
programs. If we terminate a preclinical program in which we have invested significant resources, we will have expended resources on a
program that will not provide a full return on our investment and missed the opportunity to have allocated those resources to potentially
more productive uses.

Management has discretion to terminate the development of any of our projects at any time.

In light of the costs, both
in time and expense, as well as the preclinical results and general business considerations, management may decide not to continue developing
a particular preclinical program without announcement. Management will always base its decision on what it believes to be the most efficient
use of the Company’s resources to provide the most value to its shareholders. As a result, investors may not always be aware of
the termination of a previously announced study or trial. The Company will continue to provide update on its active preclinical projects
in its SEC filings and/or press releases, as appropriate.

<div align='center'>29</div>

We may not be successful in our efforts to identify or discover additional drug candidates. Due to our limited resources and access to capital, we must continue to prioritize development of certain drug candidates; such decisions may prove to be wrong and may adversely affect Aptorum’s business.

Although we intend to explore
other therapeutic opportunities in addition to the drug candidates that we are currently developing, we may fail to identify other drug
candidates for a number of reasons. For example, our research methodology may be unsuccessful in identifying potential drug candidates
or those we identify may be shown to